ORGO Q3 2025 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$355M

Q3 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$151M+31.0% YoY

Gross Profit

$115M76.0% margin

Operating Income

$21M13.7% margin

Net Income

$22M14.3% margin

EPS (Diluted)

$0.11

QoQ Revenue Growth

+49.7%

Cash Flow

Operating Cash Flow

$3M

Free Cash Flow

$844,000

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$510M

Total Liabilities

$124M

Stockholders' Equity

$386M

Cash & Equivalents

$64M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$151M	$115M	+31.0%
Gross Profit	$115M	$88M	+29.7%
Operating Income	$21M	$6M	+232.1%
Net Income	$22M	$12M	+74.9%

Revenue Segments

Product

$150M100%

Grant

$377,0000%